The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Mohan Pankaj since 2017.
This trader's CIK number is 1664386.
At the time of last reporting, Mohan Pankaj was the Chairman, President and CEO of Sonnet Biotherapeutics Holdings, Inc.. (stock ticker symbol SONN).
Also see all insider trading activities at Sonnet Biotherapeutics Holdings, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2019 | OTLK | 8,000 | $5,440 | 0 | $0 | 0 | $0 |
2018 | OTLK | 0 | $0 | 114,677 | $134,067 | 0 | $0 |
2017 | OTLK | 0 | $0 | 104,131 | $119,324 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2023 | SONN | 465,975 | $117,966 | 0 | $0 | 0 | $0 |
2021 | SONN | 32,000 | $49,504 | 0 | $0 | 0 | $0 |
2020 | SONN | 2,400 | $9,816 | 0 | $0 | 0 | $0 |
1. Outlook Therapeutics, Inc. (OTLK)
2. Sonnet Biotherapeutics Holdings, Inc. (SONN)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2019-01-15 | OTLK | Buy | 8,000 | .68 | 5,440 |
2018-01-04 | ONS | Sale | 62,569 | 1.16 | 72,580 |
2018-01-03 | ONS | Sale | 52,108 | 1.18 | 61,487 |
2017-12-18 | ONS | Sale | 20,523 | 1.17 | 24,011 |
2017-12-19 | ONS | Sale | 83,608 | 1.14 | 95,313 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2023-10-27 | SONN | Buy | 34,375 | .00 | 0 |
2023-05-15 | SONN | Buy | 371,600 | .22 | 82,866 |
2023-03-15 | SONN | Buy | 60,000 | .58 | 35,100 |
2021-06-09 | SONN | Buy | 32,000 | 1.55 | 49,504 |
2020-06-10 | SONN | Buy | 2,400 | 4.09 | 9,816 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mohan Pankaj (Chairman, President and CEO of Sonnet Biotherapeutics Holdings, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.